4-hydroxy-5-phenylamino imidazole compound as well as preparation method and application thereof

Through the reaction of thiolid and nitrosobenzene in solvent, combining amidine hydrochloride and alkali, 4-hydroxy-5-phenylaminoimidazole compounds and α-carbonylamide compounds were successfully prepared, and the prior art was solved The harsh reaction conditions and the use of metal catalysts have achieved efficient and gentle synthesis and large-scale production of imidazole derivatives.

CN119019336AActive Publication Date: 2024-11-26ZHEJIANG UNIV CITY COLLEGE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411111151.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26
Estimated Expiration
2044-08-14

AI Technical Summary

Technical Problem

The existing imidazole derivative synthesis methods have problems such as harsh reaction conditions and the need to use metal catalysts, and lack gentle, environmentally friendly and efficient methods.

Method used

The reaction was stirred and nitrosobenzene in the solvent, and the amidine hydrochloride and alkali were added. The 4-hydroxy-5-phenylaminoimidazole compound was obtained by suction filtration and washing, and then hydrolyzed with boron trifluoride ether. To produce α-carbonyl amide compounds, the entire process does not require heavy/precious metal catalysts.

Benefits of technology

A method for efficient construction of imidazole derivatives under mild conditions has been realized, with high reaction yield, simple steps, wide applicability, and suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019336A_ABST
    Figure CN119019336A_ABST
Patent Text Reader

Abstract

The invention relates to a 4-hydroxy-5-phenyl amino imidazole compound as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving sulfur ylide and nitrosobenzene in a solvent, and stirring to react; adding amidine hydrochloride and alkali, and continuously stirring to react; and carrying out suction filtration, washing a filter cake, and drying to obtain a target compound. The method has the beneficial effects that no heavy / noble metal catalyst is needed, the reaction conditions are mild, the steps are simple, the used time is short, the reaction yield is high, and the separation yield of most products is 80% or above; the substrate is wide in application range, various substrate structures can tolerate the reaction conditions, and large-scale production is facilitated; the invention provides a method for preparing an alpha-carbonyl amide compound by using a 4-hydroxy-5-phenyl amino imidazole compound, and the reaction can be completed without a catalyst.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug synthesis, and in particular relates to a 4-hydroxy-5-phenylaminoimidazole compound and a preparation method and application thereof. Background Art

[0002] Imidazole contains two sp 2 Five-membered aromatic ring structures with hybridized nitrogen atoms are widely present in various natural products and bioactive compounds. To date, imidazole derivatives have shown therapeutic potential for treating a variety of diseases, including tropical diseases, cancer, AIDS, fungal and viral microbial infections. Therefore, they have attracted great attention from medicinal chemists.

[0003] Since most cancer therapeutic drugs contain imidazole nuclei, imidazole derivatives have become an important anchor for the development of new anticancer drugs. For example, Zhang et al. developed a series of novel 4,5-disubstituted benzyl-1-methyl-1H-imidazole-2-amine compounds and conducted biological evaluations on them through the P-gp-mediated multidrug resistant breast cancer cell line MDA435 / LCC6MDR. The results showed that one of the compounds exhibited excellent P-gp regulatory activity, low in vitro cytotoxicity, and good safety and efficacy (4,5-Di-substituted benzyl-imidazol-2-substitutedamines as the structure template for the design and synthesis of reversalagents against P-gp-mediated multidrug resistance breast cancer cells. European Journal of Medicinal Chemistry. 2014, 18, 74-83.). Albrecht et al. tested a series of p38 mitogen-activated protein kinase inhibitors, among which the most promising compound CBS-3595 was successfully evaluated in in vitro experiments and in vitro and in vivo preclinical studies (Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide(CBS-3595),a Dual p38αMAPK / PDE-4Inhibitor with Activity against TNFα-Related Diseases.Journal of Medicinal Chemistry.2017,60,5290-5305.). Loksha et al. prepared a series of imidazole derivatives similar to Capravirine or S-1153 and screened them against HIV-1. Two of the compounds have extremely low IC50 values ​​and are highly active against viral infections (Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirineanalogues. Bioorganic & Medicinal Chemistry. 2005, 13, 4209-4220.).

[0004] A variety of methods for synthesizing imidazole derivatives have been reported, which can be roughly divided into three types. The first method is to synthesize imidazole derivatives through a three-component one-pot method using the corresponding diphenylethylenedione, aldehyde or ketone and ammonium acetate; the second method uses Cu2O as a catalyst to react 2-(indol-3-yl)cyclohexanone with amidine through indole-mediated cyclization rearrangement to obtain spiroimidazole derivatives; the third method can be summarized as a [3+2] cyclization strategy. For example, Lei used a single oxygen ( 1 O2)-mediated enamine oxidation reaction with amidine to synthesize imidazoles in high yield (Lewis Acid-Relayed Singlet Oxygen Reaction with Enamines: Selective Dimerization of Enamines to Pyrrolin-4-ones. J. Am. Chem. Soc. 2022, 144, 16667-16675.). Liu used amidine compounds to bicyclize 4-cyano-1,2-dione derivatives to synthesize tetrahydro-5H-imidazo[4,5-b]pyridin-5-one (Bicyclization of 4-Cyano-1,2-diketones with Amidines: Synthesis of Tetrahydroimidazo[4,5-b]-5-pyridinones. J. Org. Chem. 2022, 87, 11274-11280.).

[0005] Although these methods have been demonstrated to be effective routes to synthesize imidazole derivatives, the above strategies still suffer from the problems of harsh reaction conditions and the need for the use of metal catalysts.

[0006] Therefore, there is an urgent need for a chemical synthesis method with mild reaction conditions, environmental friendliness, strong substrate applicability, and the ability to quickly and efficiently construct imidazole derivatives, as well as an application method of such imidazole derivatives. Summary of the invention

[0007] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a 4-hydroxy-5-phenylaminoimidazole compound and a preparation method and application thereof.

[0008] The structural formula of this 4-hydroxy-5-phenylaminoimidazole compound is:

[0009]

[0010] The R1 is a phenyl group, a substituted phenyl group, an alkyl group or a heterocyclic aromatic group, R2 is a phenyl group or a substituted phenyl group, and R3 is a phenyl group, a substituted phenyl group or a substituted alkyl group.

[0011] The preparation method of the 4-hydroxy-5-phenylaminoimidazole compound comprises the following steps:

[0012] S1, dissolving sulfur ylide and nitrosobenzene in a solvent and stirring to react;

[0013] S2, adding amidine hydrochloride and alkali to the reaction system obtained in step S1, and continuing to stir the reaction;

[0014] S3, filtering the reaction system obtained in step S3, washing the filter cake, and drying to obtain 4-hydroxy-5-phenylaminoimidazole compounds.

[0015] Preferably, in step S1, the structural formula of sulfur ylide is:

[0016]

[0017] The R1 is a phenyl group, a substituted phenyl group, an alkyl group or a heterocyclic aromatic group, and R4 is a phenyl group or an alkyl group.

[0018] Preferably, in step S1, the structural formula of nitrosobenzene is:

[0019]

[0020] The R2 is phenyl or various substituted phenyl.

[0021] Preferably, the reaction temperature ranges from 0 to 40° C.; in step 1, the stirring reaction time is 2 to 10 minutes; in step 2, the stirring reaction time is 1 to 5 hours.

[0022] Preferably, the solvent includes one or more of acetonitrile, tetrahydrofuran, 1,4-dioxane, methanol, dichloromethane and N,N-dimethylformamide.

[0023] Preferably, the base includes one or more of potassium carbonate, sodium bicarbonate, dipotassium hydrogen phosphate, ammonium carbonate and triethylamine.

[0024] Preferably, the concentration of the sulfur ylide in the solvent is 0.1-1 mmol / mL; the amount of nitrosobenzene is 1 equivalent of the sulfur ylide; the amount of the base is 1-2 equivalents of the sulfur ylide, and the amount of amidine hydrochloride is 1-2 equivalents of the sulfur ylide.

[0025] A method for preparing an α-carbonyl amide compound, wherein the 4-hydroxy-5-phenylaminoimidazole compound and boron trifluoride etherate are subjected to a hydrolysis reaction in a solvent to obtain the α-carbonyl amide compound, wherein the structure of the α-carbonyl amide compound is:

[0026]

[0027] The R1 is phenyl or substituted phenyl, and R2 is phenyl or substituted phenyl.

[0028] The beneficial effects of the present invention are:

[0029] 1) The present invention provides a method for preparing 4-hydroxy-5-phenylaminoimidazole compounds, which does not require any heavy / precious metal catalysts, has mild reaction conditions, simple steps, short reaction time, high reaction yield, and the separation yield of most products is above 80%; the substrate has a wide range of applicability, and a variety of substrate structures can tolerate the reaction conditions, which is conducive to large-scale production.

[0030] 2) The present invention provides a method for preparing α-carbonyl amide compounds using 4-hydroxy-5-phenylaminoimidazole compounds, which can also complete the reaction without the need for a catalyst, thus facilitating the large-scale production of α-carbonyl amide compounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is the hydrogen spectrum of the product of Example 3;

[0032] Figure 2 This is the carbon spectrum of the product of Example 3;

[0033] Figure 3 This is the hydrogen spectrum of the product of Example 20;

[0034] Figure 4 This is the carbon spectrum of the product of Example 20;

[0035] Figure 5 This is the hydrogen spectrum of the product of Example 28;

[0036] Figure 6 This is the carbon spectrum of the product of Example 28. DETAILED DESCRIPTION

[0037] The present invention is further described below in conjunction with embodiments. The description of the following embodiments is only used to help understand the present invention. It should be noted that for ordinary persons in the art, without departing from the principle of the present invention, the present invention can also be modified in some ways, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.

[0038] Embodiment 1

[0039] As an example, this example 1 provides a 4-hydroxy-5-phenylaminoimidazole compound and a preparation method thereof. The structural formula of the 4-hydroxy-5-phenylaminoimidazole compound is:

[0040]

[0041] The R1 is a phenyl group, a substituted phenyl group, an alkyl group or a heterocyclic aromatic group, R2 is a phenyl group or a substituted phenyl group, and R3 is a phenyl group, a substituted phenyl group or a substituted alkyl group.

[0042] The preparation method of the 4-hydroxy-5-phenylaminoimidazole compound comprises the following steps:

[0043] S1, dissolving sulfur ylide and nitrosobenzene in a solvent and stirring for reaction; wherein:

[0044] The structural formula of sulfur ylide is:

[0045]

[0046] The R1 is a phenyl group, various substituted phenyl groups, an alkyl group or a heterocyclic aromatic group, and R4 is a phenyl group or an alkyl group.

[0047] The structural formula of nitrosobenzene is:

[0048]

[0049] The R2 is phenyl or various substituted phenyl.

[0050] The solvent is selected from one or more of acetonitrile, tetrahydrofuran, 1,4-dioxane, methanol, dichloromethane and N,N-dimethylformamide.

[0051] S2, adding amidine hydrochloride and alkali to the reaction system obtained in step S1, and continuing to stir the reaction;

[0052] The base is selected from one or more of potassium carbonate, sodium bicarbonate, dipotassium hydrogen phosphate, ammonium carbonate and triethylamine.

[0053] S3. The reaction system obtained in step S3 is filtered, the filter cake is washed, and the target compound is obtained after drying.

[0054] The overall reaction formula of this preparation method is:

[0055]

[0056] Embodiment 2

[0057] As another embodiment, this embodiment 2 proposes, based on the embodiment 1, the application of this 4-hydroxy-5-phenylaminoimidazole compound:

[0058] The 4-hydroxy-5-phenylaminoimidazole compound and boron trifluoride etherate are stirred and reacted in a solvent until the 4-hydroxy-5-phenylaminoimidazole compound is completely reacted to obtain a hydrolysis product α-carbonylamide compound. The amount of boron trifluoride etherate used is 10 to 20 times the equivalent of the 4-hydroxy-5-phenylaminoimidazole compound. The solvent is selected from one or more of acetonitrile, 1,4-dioxane and dichloromethane. The reaction time is 1 to 5 hours.

[0059] The reaction equation of the hydrolysis reaction is:

[0060]

[0061] In this example, 1.0 mmol, 1.0 equivalent of 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol was dissolved in 5 mL of dichloromethane, and the reaction system was cooled to 0° C. Subsequently, 15.0 mmol, 15.0 equivalent of boron trifluoride etherate was added dropwise to the system, stirred at 0° C. for 0.5 hours, and then stirred at room temperature for 2 hours.

[0062] After the reaction is completed, the reaction system is quenched with water and extracted three times with dichloromethane. The organic phase is dried over anhydrous sodium sulfate and then rotary evaporated to obtain a crude product, which is purified by column chromatography, specifically using 200-300 mesh silica gel, petroleum ether / ethyl acetate = 10:1, and vacuum dried to obtain an α-carbonyl amide compound powder.

[0063]

[0064] The R1 is a phenyl group or various substituted phenyl groups, and R2 is a phenyl group or various substituted phenyl groups.

[0065] It should be noted that the parts in this embodiment that are the same or similar to those in the first embodiment can be referenced to each other and will not be described in detail in this application.

[0066] Embodiment 3

[0067] As another embodiment, this embodiment three proposes, based on the embodiment one, using the preparation method of this 4-hydroxy-5-phenylaminoimidazole compound to obtain a 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol, whose structural formula is:

[0068]

[0069] 1.0 mmol, 1.0 equivalent of 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one and 1.0 mmol, 1.0 equivalent of nitrosobenzene were dissolved in 5 mL of acetonitrile and stirred at room temperature for 5 minutes.

[0070] After the raw materials reacted completely, 1.0 mmol, 1.0 equivalent of benzamidine hydrochloride and 1.0 mmol, 1.0 equivalent of sodium bicarbonate were added to the system in sequence, and the mixture was stirred at room temperature for 5 hours.

[0071] After the reaction was completed, the reaction system was filtered, and the filter cake was washed with 10 mL*3 petroleum ether and 10 mL*3 water in turn, and vacuum dried to obtain 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol in the form of a white powder. The yield was 86%.

[0072] The melting point of 2,4-diphenyl-5-(phenylamino)-4H-imidazol-4-ol is 155.3-155.8°C.

[0073] like Figure 1 and Figure 2 As shown, this 2,4-diphenyl-5-(phenylamino)-4H-imidazol-4-ol:

[0074] 1 H NMR (400MHz, CDCl3): δ8.29(d,J=6.8Hz,2H),7.68(d,J=7.8Hz,2H),7.45–7.38(m,3H),7.35(m,2H),7.30(m,2H),7.19–7.14(m,2H),7.10(m,2H). 13 C NMR (100MHz, CDCl3): δ181.7,176.0,138.5,138.4,132.0,131.4,129.6,128.9,128.6,128.4,128.4,124.8,124.2,119.7,102.4. HRMS(ESI):m / z calcd for[M+H] + :328.1444,found:328.1442.

[0075] Embodiment 4

[0076] As another example, based on Example 3, Example 4 proposes that the amounts of benzamidine hydrochloride and sodium bicarbonate are adjusted to 1.5 mmol, 1.5 equivalents, and other conditions remain unchanged. After vacuum drying, 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol is also obtained as a white powder. The yield is 92% and the melting point is the same.

[0077] 1H NMR (400MHz, CDCl3): δ8.29(d,J=6.8Hz,2H),7.68(d,J=7.8Hz,2H),7.45–7.38(m,3H),7.35(m,2H),7.30(m,2H),7.19–7.14(m,2H),7.10(m,2H). 13 C NMR (100MHz, CDCl3): δ181.7,176.0,138.5,138.4,132.0,131.4,129.6,128.9,128.6,128.4,128.4,124.8,124.2,119.7,102.4. HRMS(ESI):m / z calcd for[M+H] + :328.1444,found:328.1442.

[0078] Embodiment 5

[0079] As another example, based on Example 3, this Example 5 proposes that the amounts of benzamidine hydrochloride and sodium bicarbonate are adjusted to 2.0 mmol, 2.0 equivalents, and other conditions remain unchanged. After vacuum drying, 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol is also obtained as a white powder. The yield is 90% and the melting point is the same.

[0080] 1 H NMR (400MHz, CDCl3): δ8.29(d,J=6.8Hz,2H),7.68(d,J=7.8Hz,2H),7.45–7.38(m,3H),7.35(m,2H),7.30(m,2H),7.19–7.14(m,2H),7.10(m,2H). 13 C NMR (100MHz, CDCl3): δ181.7,176.0,138.5,138.4,132.0,131.4,129.6,128.9,128.6,128.4,128.4,124.8,124.2,119.7,102.4. HRMS(ESI):m / z calcd for[M+H] + :328.1444,found:328.1442.

[0081] Embodiment 6

[0082] As another embodiment, this embodiment 6 proposes, based on the embodiment 3, to convert 2-(dimethyl-λ 4-sulfinyl)-1-phenyl-1-one and nitrosobenzene were adjusted to 0.5 mmol, 1.0 equivalent, benzamidine hydrochloride and sodium bicarbonate were adjusted to 0.75 mmol, 1.5 equivalent, and other conditions remained unchanged. After vacuum drying, 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol was obtained as a white powder. The yield was 80% and the melting point was the same.

[0083] 1 H NMR (400MHz, CDCl3): δ8.29(d,J=6.8Hz,2H),7.68(d,J=7.8Hz,2H),7.45–7.38(m,3H),7.35(m,2H),7.30(m,2H),7.19–7.14(m,2H),7.10(m,2H). 13 C NMR (100MHz, CDCl3): δ181.7,176.0,138.5,138.4,132.0,131.4,129.6,128.9,128.6,128.4,128.4,124.8,124.2,119.7,102.4. HRMS(ESI):m / z calcd for[M+H] + :328.1444,found:328.1442.

[0084] Embodiment 7

[0085] As another embodiment, this embodiment 7 proposes, based on the embodiment 3, to convert 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one and nitrosobenzene were adjusted to 2.5 mmol, 1.0 equivalent, and benzamidine hydrochloride and sodium bicarbonate were adjusted to 3.75 mmol, 1.5 equivalent. Other conditions remained unchanged, and 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol was obtained after vacuum drying as a white powder. The yield was 88%, and the melting point was the same.

[0086] 1 H NMR (400MHz, CDCl3): δ8.29(d,J=6.8Hz,2H),7.68(d,J=7.8Hz,2H),7.45–7.38(m,3H),7.35(m,2H),7.30(m,2H),7.19–7.14(m,2H),7.10(m,2H). 13C NMR (100MHz, CDCl3): δ181.7,176.0,138.5,138.4,132.0,131.4,129.6,128.9,128.6,128.4,128.4,124.8,124.2,119.7,102.4. HRMS(ESI):m / z calcd for[M+H] + :328.1444,found:328.1442.

[0087] Embodiment 8

[0088] As another embodiment, this embodiment eight is based on the embodiment three and 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced by 1-(4-chlorophenyl)-2-(dimethyl-λ 4 -sulfinyl)ethane-1-one to obtain a 4-(4-chlorophenyl)-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0089]

[0090] White powder. Yield 92%, melting point 151.9-152.3℃.

[0091] 1 H NMR (400 MHz, DMSO -D6 ): δ10.21(s,1H),8.26(d,J=6.7Hz,2H),8.06(d,J=8.0Hz,2H),7.60–7.50(m,4H),7.42(m,4H),7.36(m,2H),7.09(t,J=7.3Hz,1H). 13 C NMR (100 MHz, DMSO -D6 ): δ182.8,173.0,140.1,139.2,133.0,132.9,131.9,129.2,129.2,129.0,128.6,127.7,123.9,120.2,103.2. HRMS(ESI):m / zcalcd for[M+H] + :362.1055,found:362.1048.

[0092] Embodiment 9

[0093] As another embodiment, this embodiment 9 is based on the embodiment 3 and 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced by 2-(dimethyl-λ 4-sulfinyl)-1-(4-fluorophenyl)ethan-1-one to obtain a 4-(4-fluorophenyl)-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0094]

[0095] White powder. Yield 88%, melting point 162.4-162.8℃.

[0096] 1 H NMR (400 MHz, DMSO -D6 ): δ10.19(s,1H),8.26(d,J=6.5Hz,2H),8.07(d,J=8.0Hz,2H),7.60–7.50(m,4H) ,7.46(m,2H),7.39(t,J=7.9Hz,2H),7.17(t,J=8.9Hz,2H),7.09(t,J=7.3Hz,1H). 13 C NMR (100 MHz, DMSO -D6 ): δ182.9,172.8,162.3(d,J=242.3Hz),140.2,136.5,132.9,131.9,129.2, 129.1, 129.0, 127.9 (d, J = 8.3Hz), 123.9, 120.2, 115.4 (d, J = 21.4Hz), 103.2. HRMS(ESI):m / z calcd for[M+H] + :346.1351,found:346.1363.

[0097] Embodiment 10

[0098] As another embodiment, this embodiment 10 is based on the embodiment 3 and 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one is replaced with 2-(dimethyl-L4-sulfinyl)-1-(4-nitrophenyl)ethan-1-one to obtain a 4-(4-nitrophenyl)-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol having the structural formula:

[0099]

[0100] White powder, yield 86%, melting point 173.1-173.6℃.

[0101] 1 H NMR (400 MHz, DMSO -D6): δ10.35(s,1H),8.28(d,J=6.8Hz,2H),8.23(d,J=8.8Hz,2H),8.05(d,J=8.0Hz,2H), 7.67(d,J=8.8Hz,2H),7.61–7.54(m,4H),7.39(t,J=7.9Hz,2H),7.10(t,J=7.3Hz,1H). 13 C NMR (100 MHz, DMSO -D6 ): δ182.4,173.8,147.6,147.2,140.0,132.6,132.1,129.2,129.0,127.1,124.1,124.0,120.2,103.1. HRMS(ESI):m / zcalcd for[M+H] + :373.1296,found:373.1191.

[0102] Embodiment 11

[0103] As another embodiment, in this embodiment 11, based on the embodiment 3, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfuryl)-1-(4-cyanophenyl)ethane-1-one to obtain a 4-(4-hydroxy-2-phenyl-5-(phenylamino)-4H-imidazol-4-yl)benzonitrile, the structural formula of which is:

[0104]

[0105] White powder, yield 85%, melting point: 178.2-179.1℃.

[0106] 1 H NMR (400 MHz, DMSO -D6 ): δ10.28(s,1H),8.26(d,J=6.8Hz,2H),8.04(d,J=8.0Hz,2H),7.83(d,J=8.4Hz,2H), 7.58(d,J=8.0Hz,3H),7.56–7.49(m,3H),7.39(t,J=7.9Hz,2H),7.10(t,J=7.3Hz,1H); 13 C NMR (100 MHz, DMSO -D6): δ182.5,173.7,145.4,140.0,132.8,132.7,132.1,129.3,129.3,129.0,126.7,124.1,120.2,119.2,111.2,103.2. HRMS(ESI):m / z calcd for

[0107] [M+H]+:353.1397,found:353.1262.

[0108] Embodiment 12

[0109] As another embodiment, in this embodiment 12, based on the embodiment 3, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfurylene)-1-(4-trifluoromethylphenyl)ethane-1-one to obtain a 2-phenyl-5-(phenylamino)-4-(4-(trifluoromethyl)phenyl)-4H-imidazole-4-ol, the structural formula of which is:

[0110]

[0111] White powder, yield 68%, melting point: 173.9-174.7℃.

[0112] 1 H NMR (400 MHz, DMSO -D6 ): δ10.27(s,1H),8.27(d,J=7.0Hz,2H),8.07(d,J=8.1Hz,2H),7.74(d,J=8.4Hz,2H),7.6 3(d,J=8.2Hz,2H),7.56(m,3H),7.48(s,1H),7.39(t,J=7.8Hz,2H),7.10(t,J=7.3Hz,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ182.7,173.4,144.7,140.1,132.8,132.0,129.2,129.0,128.7(q,J=22.8Hz ), 127.1, 126.6, 125.7 (q, J = 3.3Hz), 124.4 (q, J = 210.1Hz), 124.0, 120.2, 103.2. HRMS(ESI):m / z calcd for[M+H] + :396.1319,found:396.1212.

[0113] Embodiment 13

[0114] As another embodiment, in this embodiment thirteen, based on the third embodiment, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfuryl)-1-(4-methylphenyl)ethane-1-one to obtain a 2-phenyl-5-(phenylamino)-4-(p-tolyl)-4H-imidazole-4-ol, the structural formula of which is:

[0115]

[0116] White powder, yield 91%, melting point: 167.7-167.9℃.

[0117] 1 H NMR (400 MHz, DMSO -D6 ): δ10.08(s,1H),8.32–8.21(m,2H),8.08(d,J=8.0Hz,2H),7.54(m,3H),7.38(t,J=7.9H z,2H),7.32(d,J=8.1Hz,2H),7.15(t,J=3.9Hz,3H),7.08(t,J=7.3Hz,1H),2.27(s,3H); 13 C NMR (100 MHz, DMSO -D6 ): δ183.2,172.4,140.3,137.5,137.3,133.1,131.7,129.2,129.1,129.1,128.9,125.6,123.8,120.1,103.6,21.2. HRMS(ESI):m / z calcd for[M+H] + :342.1601,found:342.1601.

[0118] Embodiment 14

[0119] As another embodiment, in this embodiment 14, based on the embodiment 3, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfuryl)-1-(4-methoxyphenyl)ethane-1-one to obtain a 4-(4-methoxyphenyl)-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0120]

[0121] White powder, yield 77%, melting point: 168.4-169.3℃.

[0122] 1 H NMR (400 MHz, DMSO -D6 ): δ10.09(s,1H),8.26(d,J=6.3Hz,2H),8.08(d,J=8.0Hz,2H),7.56(d,J=6.2Hz,2H),7.52(d,J=5.9Hz,1H ),7.41–7.36(m,3H),7.34(s,1H),7.13(s,1H),7.08(t,J=7.3Hz,1H),6.90(d,J=8.7Hz,2H),3.72(s,3H); 13 C NMR (100 MHz, DMSO -D6 ): δ188.1,185.2,137.7,136.4,135.9,133.5,129.5,129.5,129.2,127.5,122.2,122.1. HRMS(ESI):m / z calcd for[M+H] + :358.1551,found:358.1550.

[0123] Embodiment 15

[0124] As another embodiment, in this embodiment 15, based on the embodiment 3, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfuryl)-1-(3-methoxyphenyl)ethane-1-one to obtain a 4-(3-methoxyphenyl)-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0125]

[0126] White powder, yield 61%, melting point: 179.9-180.5℃.

[0127] 1 H NMR (400 MHz, DMSO -D6 ): δ10.15(s,1H),8.29(d,J=6.7Hz,2H),8.10(d,J=8.0Hz,2H),7.60–7.54(m,3H),7.40(t,J=7.7Hz ,2H),7.25(d,J=6.2Hz,2H),7.19(s,1H),7.11(t,J=7.3Hz,1H),6.88(t,J=9.6Hz,2H),3.77(s,3H); 13 C NMR (100 MHz, DMSO -D6): δ183.1,172.8,159.6,141.8,140.2,133.0,131.8,129.7,129.2,129.1,129.0,123.8,120.2,117.7,113.5,111.9,103.5,55.5. HRMS(ESI):m / z calcd for[M+H] + :358.1551,found:358.1437.

[0128] Embodiment 16

[0129] As another embodiment, in this embodiment 16, based on the embodiment 3, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfuryl)-1-(2-methoxyphenyl)ethane-1-one to obtain a 4-(2-methoxyphenyl)-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0130]

[0131] White powder, yield 71%, melting point: 163.7-164.7℃.

[0132] 1 H NMR (400 MHz, DMSO -D6 ): δ10.13(s,1H),8.28–8.24(m,2H),8.07(d,J=7.9Hz,2H),7.59–7.55(m,2H),7.54(s,1H),7.38(t,J=7.9Hz,2H),7 .23(d,J=5.4Hz,2H),7.15(d,J=1.7Hz,1H),7.08(t,J=7.3Hz,1H),6.87(m,1H),6.83(d,J=7.9Hz,1H),3.75(s,3H); 13 C NMR (100 MHz, DMSO -D6 ):

[0133] δ183.0,172.8,159.6,141.8,140.2,133.0,131.8,129.7,129.2,129.1,129.0,123.8,120.1,117.6,113.5,111.9,103.5,55.5. HRMS(ESI):m / z calcd for

[0134] [M+H] +:358.1551,found:358.1470.

[0135] Embodiment 17

[0136] As another embodiment, this embodiment 17 is based on the embodiment 3 and the 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfuryl)-1-(furan-2-yl)ethane-1-one to obtain a 4-(furan-2-yl)-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0137]

[0138] White powder, yield 82%, melting point: 188.1-188.6℃.

[0139] 1 H NMR (400 MHz, DMSO -D6 ): δ10.42(s,1H),8.24(d,J=7.2Hz,2H),8.11(d,J=8.2Hz,2H),7.61(s,1H),7.55 (m,3H),7.40(t,J=7.9Hz,2H),7.36(s,1H),7.11(t,J=7.4Hz,1H),6.46(m,2H).; 13 C NMR (100 MHz, DMSO -D6 ): δ180.8,173.5,152.8,143.3,140.1,132.9,131.9,129.2,129.2,129.0,124.0,120.2,110.9,108.0,100.1. HRMS(ESI):m / zcalcd for[M+H] + :318.1238,found:318.1187.

[0140] Embodiment 18

[0141] As another embodiment, in this embodiment 18, based on the third embodiment, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 2-(dimethyl-λ 4 -sulfonyldiene)-1-(thiophen-2-yl)ethane-1-one to obtain a 2-phenyl-5-(phenylamino)-4-(thiophen-2-yl)-4H-imidazole-4-ol, the structural formula of which is:

[0142]

[0143] White powder, yield 81%, melting point: 166.6-167.1℃.

[0144] 1 H NMR (400 MHz, DMSO -D6 ): δ10.45(s,1H),8.29–8.21(m,2H),8.12(d,J=8.0Hz,2H),7.58–7.52(m,3H),7.48–7. 43(m,2H),7.41(t,J=7.9Hz,2H),7.21–7.17(m,1H),7.11(t,J=7.4Hz,1H),6.99(m,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ181.8,172.8,144.9,140.2,132.9,131.9,129.2,129.1,129.0,127.2,126.3,125.0,124.0,120.3,101.6. HRMS(ESI):m / z calcd for[M+H] + :334.1009,found:334.1009.

[0145] Embodiment 19

[0146] As another embodiment, in this embodiment 19, based on the embodiment 3, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 1-(dimethyl-λ 4 -sulfuryl)-4-phenylbutane-2-one to obtain a 4-phenylethyl-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0147]

[0148] White powder, yield 93%, melting point: 172.2-173.2℃.

[0149] 1 H NMR (400 MHz, DMSO -D6): δ10.32(s,1H),8.31–8.23(m,2H),8.09(d,J=8.0Hz,2H),7.54(d,J=6.5Hz,3H),7.40(t,J=7.8Hz,2H),7.25–7.20(m,2H),7.13(d ,J=7.1Hz,3H),7.09(d,J=7.3Hz,1H),6.57(s,1H),2.58(dd,J=18.8,6.5Hz,1H),2.45–2.31(m,2H),2.06(dd,J=18.3,6.3Hz,1H).; 13 C NMR (100 MHz, DMSO -D6 ): δ182.5,171.9,142.0,140.4,133.3,131.5,129.2,129.0,128.8,128.7,128.5,126.1,123.7,120.0,103.0,39.6,29.6. HRMS(ESI):m / z calcd for[M+H] + :356.1758,found:356.1753.

[0150] Embodiment 20

[0151] As another embodiment, in this embodiment 20, based on the embodiment 3, 2-(dimethyl-λ 4 -sulfinyl)-1-phenyl-1-one was replaced with 1-cyclohexyl-2-(dimethyl-λ 4 -sulfonyl diene)ethane-1-one to obtain a 4-cyclohexyl-2-phenyl-5-(phenylamino)-4H-imidazole-4-ol, the structural formula of which is:

[0152]

[0153] White powder, yield 95%, melting point: 160.2-160.9℃. Figure 3 and Figure 4 As shown:

[0154] 1 H NMR (400 MHz, DMSO -D6): δ10.14(s,1H),8.25–8.18(m,2H),8.08(d,J=8.0Hz,2H),7.51(d,J=6.6Hz,3H) ,7.38(t,J=7.8Hz,2H),7.07(t,J=7.3Hz,1H),6.31(s,1H),2.30(d,J=12.6Hz,1H) ,1.93(t,J=11.6Hz,1H),1.80(d,J=12.2Hz,1H),1.61–1.52(m,2H),1.41(td,J=13 .0,2.6Hz,1H),1.20(d,J=12.6Hz,1H),1.08(t,J=13.2Hz,3H),0.72–0.56(m,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ183.3,172.0,140.4,133.4,131.4,129.2,129.0,128.8,123.5,119.9,105.2,44.8,27.2,26.5,26.5,25.9,25.7. HRMS(ESI):m / z calcd for[M+H] + :334.1914,found:334.1910.

[0155] Embodiment 21

[0156] As another embodiment, in Embodiment 21, based on Embodiment 3, nitrosobenzene is replaced with 1-chloro-4-nitrosobenzene to obtain 5-((4-chlorophenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0157]

[0158] White powder, yield 75%, melting point: 167.5-168.1℃.

[0159] 1 H NMR (400 MHz, DMSO -D6 ): δ10.30(s,1H),8.26(d,J=6.6Hz,2H),8.12(d,J=8.9Hz,2H),7.59(d,J=7.8Hz,1H),7.55(s,1H),7.54(s,1H ),7.46(s,1H),7.42(d,J=7.3Hz,3H),7.38(d,J=8.2Hz,1H),7.35(s,1H),7.32(d,J=5.5Hz,1H),7.26(s,1H); 13 CNMR (100MHz, DMSO-D6 ): δ183.1,172.3,140.0,139.2,132.9,131.9,129.1,129.0,128.7,128.50 126.1,125.9,125.7,121.8,103.8. HRMS(ESI):m / z calcd for[M+H] + :362.1055,found:362.1057.

[0160] Embodiment 22

[0161] As another embodiment, in Embodiment 22, based on Embodiment 3, nitrosobenzene is replaced with 1-bromo-4-nitrosobenzene to obtain 5-((4-bromophenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0162]

[0163] White powder, yield 74%, melting point: 182.6-183.1℃.

[0164] 1 H NMR (400 MHz, DMSO -D6 ): δ10.29(s,1H),8.30–8.23(m,2H),8.06(d,J=8.9Hz,2H),7.57(m,4H),7.53(s,1H),7.44–7 .43(m,1H),7.41(s,1H),7.38(d,J=7.8Hz,1H),7.35(s,1H),7.33–7.31(m,1H),7.26(s,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ183.2,172.3,139.9,139.6,132.0,131.4,129.1,129.0,128.7,128.5,126.3,125.7,122.2,115.7,103.8. HRMS(ESI):m / z calcd for[M+H] + :406.0445and 408.0429.

[0165] Embodiment 23

[0166] As another embodiment, in Embodiment 23, based on Embodiment 3, nitrosobenzene is replaced with 1-trifluoromethyl-4-nitrosobenzene to obtain 2,4-diphenyl-5-((4-(trifluoromethyl)phenyl)amino)-4H-imidazole-4-ol, whose structural formula is:

[0167]

[0168] White powder, yield 76%, melting point: 166.7-167.7℃.

[0169] 1 H NMR (400 MHz, DMSO -D6 ): δ10.26(s,1H),8.13(d,J=8.2Hz,2H),8.03(d,J=8.0Hz,2H),7.69–7.63(m,4H),7.53–7.48(m,5H),7.34(t,J=7.4Hz,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ183.5,172.2,143.6,139.7,132.7,132.0,129.3,129.2,129.1,129.0,128. 7 (q, J = 18.4Hz), 126.6 (q, J = 3.5Hz), 125.7, 125.0 (q, J = 207.7Hz), 120.3, 104.0. HRMS(ESI):m / z calcd for[M+H] + :396.1319,found:396.1255.

[0170] Embodiment 24

[0171] As another embodiment, in Embodiment 24, based on Embodiment 3, nitrosobenzene is replaced with 1-methyl-4-nitrosobenzene to obtain 2,4-diphenyl-5-(p-tolylamino)-4H-imidazole-4-ol, whose structural formula is:

[0172]

[0173] White powder, yield 67%, melting point: 154.7-155.4℃.

[0174] 1 H NMR (400 MHz, DMSO -D6 ): δ10.03(s,1H),8.25(d,J=6.4Hz,2H),7.95(d,J=7.8Hz,2H),7.54(d,J=7.0Hz ,4H),7.43(d,J=7.0Hz,2H),7.38–7.26(m,4H),7.22–7.11(m,4H),2.28(s,3H); 13 C NMR (100 MHz, DMSO -D6): δ182.9,172.7,140.4,137.8,133.2,132.8,131.7,129.6,129.1,128.9,128.6,128.3,125.7,120.2,103.5,20.9. HRMS(ESI):m / zcalcd for[M+H] + :342.1601,found:342.1578.

[0175] Embodiment 25

[0176] As another embodiment, in Embodiment 25, based on Embodiment 3, nitrosobenzene is replaced with 1-methoxy-4-nitrosobenzene to obtain 5-((4-methoxyphenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0177]

[0178] White powder, yield 65%, melting point: 170.7-171.3℃.

[0179] 1 H NMR (400 MHz, DMSO -D6 ): δ10.04(s,1H),8.25(d,J=6.7Hz,2H),8.01(d,J=8.9Hz,2H),7.54(t,J=7.4Hz,3H),7.44(s,1H),7.4 2(s,1H),7.35(t,J=7.3Hz,2H),7.30(d,J=7.0Hz,1H),7.16(s,1H),6.96(d,J=8.9Hz,2H),3.74(s,3H); 13 C NMR (100 MHz, DMSO -D6 ): δ182.7,172.8,155.8,140.6,133.7,133.3,131.7,129.1,128.9,128.6,128.3,125.7,121.6,114.4,103.4,55.7. HRMS(ESI):m / z calcd for[M+H] + :358.1551,found:358.1474.

[0180] Embodiment 26

[0181] As another example, in Example 26, based on Example 3, nitrosobenzene is replaced with 1-ethoxy-4-nitrosobenzene to obtain 5-((4-ethoxyphenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0182]

[0183] White powder, yield 59%, melting point: 162.3-163.1℃.

[0184] 1 H NMR (400 MHz, DMSO -D6 ): δ10.00(s,1H),8.25(d,J=7.3Hz,2H),7.98(d,J=8.8Hz,2H),7.55–7.50(m,3H),7.43(d,J=7.5Hz,2 H),7.32(m,3H),7.12(s,1H),6.95(s,1H),6.93(s,1H),4.01(d,J=6.9Hz,2H),1.32(t,J=6.9Hz,3H).; 13 C NMR (100 MHz, DMSO -D6 ): δ182.6,172.8,155.0,140.6,133.5,133.30,131.6,129.1,128.9,128.6,128.3,125.7,121.5,114.8,103.4,63.6,15.1. HRMS(ESI):m / z calcd for[M+Na] + :372.1707,found:372.1665.

[0185] Embodiment 27

[0186] As another embodiment, in Embodiment 27, based on Embodiment 3, nitrosobenzene is replaced with 1-isopropyl-3-nitrosobenzene to obtain 5-((4-isopropylphenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0187]

[0188] White powder, yield 78%, melting point: 174.4-174.7℃, such as Figure 5 and Figure 6 As shown:

[0189] 1 H NMR (400 MHz, DMSO -D6): δ10.06(s,1H),8.25(d,J=6.4Hz,2H),7.97(d,J=7.8Hz,2H),7.54(d,J=7.1Hz,3H),7.43(d,J=7.0Hz,2H) ,7.36–7.29(m,3H),7.28–7.22(m,2H),7.16(s,1H),2.86(dt,J=13.7,6.9Hz,1H),1.20(s,3H),1.19(s,3H); 13 C NMR (100 MHz, DMSO -D6 ): δ182.9,172.7,143.9,140.5,138.1,133.2,131.7,129.1,128.9,128.5,128.3,126.9,125.7,120.3,103.5,33.3,24.4. HRMS(ESI):370.1914,found:370.1883.

[0190] Embodiment 28

[0191] As another embodiment, in Embodiment 28, based on Embodiment 3, nitrosobenzene is replaced with 1-bromo-3-nitrosobenzene to obtain 5-((3-bromophenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0192]

[0193] White powder, yield 54%, melting point: 164.9-165.9℃.

[0194] 1 H NMR (400 MHz, DMSO -D6 ): δ10.28(s,1H),8.40(s,1H),8.24(d,J=6.6Hz,2H),8.15(d,J=7.5Hz,1H),8.06(d,J=8.0Hz, 1H),7.57(t,J=7.4Hz,3H),7.42(d,J=7.5Hz,2H),7.34(d,J=8.3Hz,3H),7.25(d,J=3.3Hz,2H); 13 CNMR (100MHz, DMSO -D6 ): δ183.3,172.2,141.7,139.8,131.9,131.2,129.3,129.0,128.7,128.5,126.4,126.1,125.7,122.6,122.0,119.0,103.9. HRMS(ESI):m / zcalcd for[M+H]+ :406.0550,found:406.0510.

[0195] Embodiment 29

[0196] As another embodiment, in Embodiment 29, based on Embodiment 3, nitrosobenzene is replaced with 1-bromo-3-nitrosobenzene to obtain 2,4-diphenyl-5-(m-tolylamino)-4H-imidazole-4-ol, whose structural formula is:

[0197]

[0198] White powder, yield 60%, melting point: 165.3-166.1℃.

[0199] (400MHz,DMSO -D6 ): δ10.02(s,1H),8.27–8.22(m,2H),7.91(d,J=8.3Hz,1H),7.85(s,1H),7.56(d,J=6.8Hz,2H),7.53(s,1H ),7.44–7.40(m,2H),7.33(m,3H),7.26(t,J=7.8Hz,1H),7.17(s,1H),6.90(d,J=7.5Hz,1H),2.32(s,3H); 13 C NMR (100 MHz, DMSO -D6 ): δ183.1,172.6,140.3,140.2,138.3,133.1,131.8,129.1,129.0,128.9,128.6,128.3,125.7,124.5,120.7,117.4,103.6,21.8. HRMS(ESI):m / z calcd for[M+H] + :342.1601,found:342.1605.

[0200] Embodiment 30

[0201] As another embodiment, in this embodiment 30, based on the embodiment 3, nitrosobenzene is replaced with 2,4-dichloro-1-nitrosobenzene to obtain 5-((2,4-dichlorophenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0202]

[0203] White powder, yield 50%, melting point: 169.9-170.3℃.

[0204] 1H NMR (400 MHz, DMSO -D6 ): δ10.53(s,1H),8.11(d,J=7.4Hz,2H),7.66(t,J=7.4Hz,1H),7.57(m,4H),7.47 (d,J=2.2Hz,1H),7.39(t,J=7.3Hz,2H),7.36–7.28(m,3H),7.25(d,J=8.6Hz,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ175.4,172.2,147.2,141.4,133.7,129.3,129.1,128.8,128.6,128.4,128.3,127.5,127.4,127.1,126.3,125.3,90.1. HRMS(ESI):m / z calcd for[M+H] + :396.0665,found:396.0669.

[0205] Embodiment 31

[0206] As another embodiment, in Embodiment 31, nitrosobenzene is replaced with 2,4-dibromo-1-nitrosobenzene on the basis of Embodiment 3 to obtain 5-((2,4-dibromophenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol, whose structural formula is:

[0207]

[0208] White powder, yield 76%, melting point: 133.5-134.3℃.

[0209] 1 H NMR (400 MHz, DMSO -D6 ): δ10.53(s,1H),8.11(d,J=7.4Hz,2H),7.72(d,J=2.1Hz,1H),7.66(t,J=7.4Hz,1H),7.61–7.53(m, 4H),7.47(m,1H),7.39(t,J=7.3Hz,2H),7.34(d,J=7.1Hz,1H),7.30(s,1H),7.18(d,J=8.5Hz,1H).; 13 C NMR (100 MHz, DMSO -D6): δ175.1,172.3,148.9,141.2,134.2,133.8,130.9,129.3,129.1,128.6,128.4,128.3,126.4,125.7,118.3,115.0,90.1. HRMS(ESI):m / z calcd for[M+H] + :375.9169, found:375.9195.

[0210] Embodiment 32

[0211] As another embodiment, in this embodiment thirty-two, on the basis of embodiment three, benzamidine hydrochloride is replaced with p-chlorobenzamidine hydrochloride to obtain a 2-(4-chlorophenyl)-4-phenyl-5-(phenylamino)-4H-imidazole-4-ol having the structural formula:

[0212]

[0213] White powder, yield 98%, melting point: 166.8-167.1℃.

[0214] 1 H NMR (400 MHz, DMSO -D6 ): δ10.18(s,1H),8.25(d,J=7.8Hz,2H),8.06(d,J=7.4Hz,2H),7.60(d,J=7.8Hz,2H),7.43(d,J=6.7H z,2H),7.37(d,J=10.6Hz,3H),7.33(d,J=5.0Hz,1H),7.30(s,1H),7.22(s,1H),7.09(t,J=6.6Hz,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ183.3,171.7,140.1,140.1,136.5,131.9,130.8,129.2,129.1,128.6,128.4,125.7,124.0,103.8. HRMS(ESI):m / z calcd for[M+H] + :362.1055,found:362.1000.

[0215] Embodiment 33

[0216] As another embodiment, in this embodiment thirty-three, on the basis of embodiment three, benzamidine hydrochloride is replaced with p-bromobenzamidine hydrochloride to obtain a 2-(4-bromophenyl)-4-phenyl-5-(phenylamino)-4H-imidazole-4-ol, whose structural formula is:

[0217]

[0218] White powder, yield 96%, melting point: 175.7-176.3℃.

[0219] 1 H NMR (400 MHz, DMSO -D6 ): δ10.18(s,1H),8.18(d,J=8.0Hz,2H),8.06(d,J=7.8Hz,2H),7.74(d,J=8.1Hz,2H),7.43(d,J=7.2Hz,2 H),7.39–7.34(m,3H),7.32(d,J=5.1Hz,1H),7.28(d,J=14.9Hz,1H),7.22(s,1H),7.09(t,J=7.1Hz,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ183.3,171.8,140.1,140.0,132.3,132.1,131.0,129.2,128.6,128.4,125.7,125.5,124.0,120.3,103.8. HRMS(ESI):m / z calcd for[M+H] + :406.0550and 408.0530,found:406.0442and 408.0444.

[0220] Embodiment 34

[0221] As another embodiment, in Embodiment 34, on the basis of Embodiment 3, benzamidine hydrochloride is replaced with cyclopropylformamidine hydrochloride to obtain a 2-cyclopropyl-4-phenyl-5-(phenylamino)-4H-imidazole-4-ol having the structural formula:

[0222]

[0223] White powder, yield 77%, melting point: 169.6-170.4℃.

[0224] 1 H NMR (400 MHz, DMSO -D6): δ9.79(d,J=12.0Hz,1H),7.88(d,J=7.9Hz,1H),7.45(d,J=7.5Hz,1H),7.36(d,J=7.6Hz,2H),7.33–7.25(m,3H),7.19(t ,J=7.5Hz,1H),7.08(d,J=7.6Hz,1H),6.95–6.90(m,1H),1.85–1.74(m,1H),1.08(d,J=9.8Hz,3H),0.95(d,J=7.7Hz,1H); 13 C NMR (100 MHz, DMSO -D6 ): δ182.7,179.2,150.2,140.5,129.0,128.4,128.1,126.0,123.9,123.0,103.1,13.0,9.9,7.6. HRMS(ESI):m / z calcd for[M+Na] + :292.1445,found:292.1392.

[0225] Embodiment 35

[0226] As another embodiment, this embodiment thirty-fifth proposes, based on the embodiment two, a preparation of 2-oxo-N,2-diphenylacetamide:

[0227] 1.0 mmol, 1.0 equivalent of 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol was dissolved in 5 mL of dichloromethane, and the reaction system was cooled to 0°C. Subsequently, 15.0 mmol, 15.0 equivalent of boron trifluoride ether was added dropwise to the system, stirred at 0°C for 0.5 hours, and then stirred at room temperature for 2 hours. The other steps and conditions were the same as those in Example 2, and finally 2-oxo-N, 2-diphenylacetamide yellow powder was obtained.

[0228] Yield: 77%, melting point: 60.3-60.9°C. Its structural formula is:

[0229]

[0230] 1 H NMR (400MHz, CDCl3): δ9.02 (s, 1H), 8.40 (d, J = 7.5Hz, 2H), 7.71 (d, J = 8.1Hz, 2H), 7.65 (m, 1H), 7.50 (m, 2H), 7.40 (m, 2H), 7.19 (m, 1H); 13C NMR (100MHz, CDCl3): δ187.4,158.9,136.6,134.6,133.1,131.5,129.2,128.6,125.3,119.9. HRMS(ESI):m / z calcd for[M+H] + :225.0790,found:225.0795.

[0231] Embodiment 36

[0232] As another embodiment, this embodiment thirty-six is ​​proposed on the basis of embodiment thirty-fifth, replacing 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol with 2-phenyl-5-(phenylamino)-4-(p-tolyl)-4H-imidazole-4-ol to obtain a 2-oxo-N-phenyl-2-(p-tolyl)acetamide brown powder with a yield of 80% and a melting point of 115.6-116.4°C.

[0233] Its structural formula is:

[0234]

[0235] 1 H NMR (400MHz, CDCl3): δ8.96 (s, 1H), 8.35 (d, J = 8.1Hz, 2H), 7.70 (d, J = 8.5Hz, 2H), 7.40(t,J=8.5Hz,2H),7.31(d,J=8.1Hz,2H),7.19(t,J=7.4Hz,1H),2.45(s,3H); 13 CNMR (100MHz, CDCl3): δ186.9,159.3,146.2,136.8,131.8,130.7,129.4,129.3,125.4,120.0,22.1. HRMS(ESI):m / z calcd for[M+H] + :240.1020,found:240.1028.

[0236] Embodiment 37

[0237] As another embodiment, this embodiment thirty-seven is proposed on the basis of embodiment thirty-five, replacing 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol with 5-((4-chlorophenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol to obtain a yellow powder of N-(4-chlorophenyl)-2-oxo-2-phenylacetamide with a yield of 72% and a melting point of 129.6-130.4°C.

[0238] Its structural formula is:

[0239]

[0240] 1 H NMR (400MHz, CDCl3) δ9.0 (s, 1H), 8.40 (d, J = 6.7Hz, 2H), 7.66 (d, J = 8.9Hz, 3H), 7.51 (t, J = 7.8Hz, 2H), 7.36 (d, J = 8.8Hz, 2H); 13 C NMR (100MHz, CDCl3) δ187.2,158.9,135.3,134.9,133.0,131.6,130.5,129.4,128.8,121.3. HRMS(ESI):m / z calcd for[M+H] + :260.0473,found:260.0488.

[0241] Embodiment 38

[0242] As another embodiment, this embodiment thirty-eight is proposed on the basis of embodiment thirty-five, replacing 2,4-diphenyl-5-(phenylamino)-4H-imidazole-4-ol with 5-((4-methoxyphenyl)amino)-2,4-diphenyl-4H-imidazole-4-ol to obtain a white powder of N-(4-methoxyphenyl)-2-oxo-2-phenylacetamide with a yield of 68% and a melting point of 102.6-103.4°C.

[0243] Its structural formula is:

[0244]

[0245] 1 H NMR (400MHz, CDCl3) δ8.89(s,1H),8.42(d,J=9.8Hz,1H),7.77–7.55(m,4H),7.51(t,J=7.9Hz,2H),6.93(d,J=9.0Hz,2H),3.83(s,3H); 13 C NMR (100MHz, CDCl3) δ187.7,158.7,157.2,134.7,133.3,131.6,129.9,128.7,121.6,114.5,55.6. HRMS(ESI):m / z calcd for[M+H] + :256.0969,found:256.0952.

[0246] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other and will not be repeated in this application.

Claims

1. A 4-hydroxy-5-phenylaminoimidazole compound, characterized in that: Its structural formula is: The R1 is a phenyl group, a substituted phenyl group, an alkyl group or a heterocyclic aromatic group, R2 is a phenyl group or a substituted phenyl group, and R3 is a phenyl group, a substituted phenyl group or a substituted alkyl group.

2. The method for preparing 4-hydroxy-5-phenylaminoimidazole compounds according to claim 1, characterized in that: The following steps are involved: S1, dissolving sulfur ylide and nitrosobenzene in a solvent and stirring to react; S2, adding amidine hydrochloride and alkali to the reaction system obtained in step S1, and continuing to stir the reaction; S3, filtering the reaction system obtained in step S3, washing the filter cake, and drying to obtain 4-hydroxy-5-phenylaminoimidazole compounds.

3. The method for preparing 4-hydroxy-5-phenylaminoimidazole compounds according to claim 2, characterized in that: In step S1, the structural formula of sulfur ylide is: The R1 is a phenyl group, a substituted phenyl group, an alkyl group or a heterocyclic aromatic group, and R4 is a phenyl group or an alkyl group.

4. The method for preparing 4-hydroxy-5-phenylaminoimidazole compounds according to claim 2, characterized in that: In step S1, the structural formula of nitrosobenzene is: The R2 is phenyl or various substituted phenyl.

5. The method for preparing 4-hydroxy-5-phenylaminoimidazole compounds according to claim 2, characterized in that: The reaction temperature ranges from 0 to 40° C.; in step 1, the stirring reaction time is 2 to 10 minutes; in step 2, the stirring reaction time is 1 to 5 hours.

6. The method for preparing 4-hydroxy-5-phenylaminoimidazole compounds according to claim 2, characterized in that: The solvent includes one or more of acetonitrile, tetrahydrofuran, 1,4-dioxane, methanol, dichloromethane and N,N-dimethylformamide.

7. The method for preparing 4-hydroxy-5-phenylaminoimidazole compounds according to claim 2, characterized in that: The base includes one or more of potassium carbonate, sodium bicarbonate, dipotassium hydrogen phosphate, ammonium carbonate and triethylamine.

8. The method for preparing 4-hydroxy-5-phenylaminoimidazole compounds according to claim 2, characterized in that: The concentration of the sulfur ylide in the solvent is 0.1-1 mmol / mL; the amount of nitrosobenzene used is 1 equivalent of the sulfur ylide; the amount of the base used is 1-2 equivalents of the sulfur ylide, and the amount of amidine hydrochloride used is 1-2 equivalents of the sulfur ylide.

9. A method for preparing an α-carbonyl amide compound, characterized in that: The α-carbonyl amide compound is obtained by hydrolyzing the 4-hydroxy-5-phenylaminoimidazole compound of claim 1 and boron trifluoride etherate in a solvent. The structure of the α-carbonyl amide compound is: The R1 is phenyl or substituted phenyl, and R2 is phenyl or substituted phenyl.

Citation Information

Patent Citations

  • Diarylformyl substituted pyrazole compound and preparation method thereof

    CN112876416A

  • Preparation method and application of N-heterocyclic carbene catalyzed cyclopropane skeleton-containing ketene compound

    CN114644578A

  • Benzo-aza compound and preparation method thereof

    CN118271243A

  • Process for preparing 4-substituted imidazole compounds

    US4215217A